Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets

This product will be manufactured at Lupin’s Pithampur facility in India

Lupin receives EIR from US FDA for its Somerset manufacturing facility

The facility was inspected from May 7 to May 17, 2024

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,

Lupin and Fuji sign agreement for commercialization of Nextstellis in Vietnam and Philippines

USFDA inspection of Lupin’s Nagpur injectable facility with zero 483 observations

Lupin completes acquisition of two brands from Sanofi in Europe and Canada

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets

Lupin receives USFDA approval for travoprost ophthalmic solution

Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Lupin launches Mirabegron Extended-Release Tablets in US

Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US

USFDA completes inspection of Lupin's Dabhasa facility with no observations

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations